ROL

Rollins is a high-quality, recurring-revenue compounder. FY2025 revenue hit $3.76B (+11.0% YoY), the fifth straight year of growth from $2.42B in FY2021, split between 6.9% organic growth and 4.1% acquisition contribution from 26 completed transactions. Net income reached $527M (+12.9%) and diluted EPS $1.09 (+13.5%), with a 38.3% return on equity that reflects an asset-light, contract-based model in pest and termite control. Operating cash flow of $678M against just $28.1M of capex confirms the capital efficiency that makes the roll-up strategy self-funding.

The issue is price, not quality. At $44.96 the stock trades at 41.2x FY EPS and 5.8x sales. That multiple demands continued flawless execution, yet management flagged that 2025 operating margin slipped 10bp to 19.3% on 'weaker volumes in the fourth quarter,' and the MD&A leans on adjusted (non-GAAP) operating margin of 20.0% to show improvement. The balance sheet is sound but leverage is creeping: long-term debt rose 23.0% to $486M and total liabilities grew 18.6% versus only 3.3% equity growth, pushing liabilities/equity to 1.29x as the company funds buybacks (cash repurchases jumped to $217M) and a $328M dividend.